Avid Bioservices to Present At Biologics Manufacturing Conference
Treat is Avid's head of business development and has expertise in the manufacture of biologics, such as purified proteins and monoclonal antibodies, which are used as therapeutics and diagnostic tools by biopharmaceutical companies.
The presentation will address issues biological contract manufacturers face in order to support current Good Manufacturing Practices (cGMP) and federal Food and Drug Administration regulations while servicing multiple clients with varied needs.
Treat will focus on the impact of one critical raw material -- powder cell culture media -- and how varied powder manufacturing processes result in unique service and manufacturing challenges for contract organizations. The presentation will include an overview of the current powder media manufacturing processes and details on how manufacturers can meet their clients' specific quality and regulatory requirements.
With 15 years of biopharmaceutical industry experience, Treat facilitates new business contracts for Avid, which manufactures antibodies and proteins in stirred tank bioreactors using mammalian cell systems. In addition to his sales experience, he has expertise in the manufacture of biologics; development of liquid and powder media, buffers and flexible packaging systems; sterilization, design control and Water for Injection systems; and bioprocess development and scale-up improvements.
About Avid Bioservices Inc.Avid Bioservices provides a full range of cGMP contract manufacturing services for the biotechnology and biopharmaceutical industries. The company's comprehensive package of services includes highly specialized cell culture, process and analytical development work, in addition to full-scale manufacturing, purification, bulk packaging and regulatory support. For more information about Avid, visit www.avidbio.com.
Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the company's expectations as a result of risk factors discussed in Peregrine's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, the company's report on Form 10-K for the year ended April 30, 2001 and on Form 10-Q for the quarter ended Jan. 31, 2002.
CONTACT: Atkins + Associates Pam Lord (media), 858/860-0266, ext. 103 plord@irpr.com or Hawk Associates Inc. Frank Hawkins (investors), 800/987-8256 http://www.hawkassociates.com
URL: http://www.businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page.
Copyright © 2002 Business Wire. All rights reserved.